This week, we will be discussing a very important topic, of which a lot of people have never heard while others have only rudimentary knowledge about the condition.
Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...